Verici was incorporated in April 2020 as a wholly-owned subsidiary of Renalytix AI plc ("RENX"), the AIM-quoted developer of artificial intelligence decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. The Company develops tests to understand how a patient is likely and may be responding to kidney transplant.